Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis Pharma
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A single center, phase I, partially blinded, placebo-controlled, first-in-man study to evaluate the safety, tolerability and Proof of Mechanism (PoM) of a single administration of BFH772 in healthy volunteers, and Proof of Concept (PoC) study to evaluate the safety, tolerability, and pharmacodynamics of multiple topical administrations of BFH772 in patients with psoriasis
• Investigate the safety and tolerability of single and multiple doses of BFH772 in two different formulations in healthy and psoriatic subjects • Assess the efficacy of topically applied BFH772 to tr...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
An open-label extension study to evaluate the long-term safety and tolerability of Sandostatin LAR in the treatment of patients with moderately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathy (PDR)
To assess the long-term safety and tolerability of open-label treatment with Sandostatin LAR 30 mg in patients who completed the double-masked study CSMS995 0802
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 5 ans
An open-label, multi-center trial to evaluate the feasibility and safety of short-term treatment with subcutaneously injected certoparin (8000 U anti-Xa twice daily) in patients with persistent nonvalvular atrial fibrillation
Primary objective is to document the feasibility and safety of short-term treatment with a fixed, body weight-independent certoparin regimen (8000 U anti-Xa twice daily) in patients with persistent no...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A 16-day, randomized, double-blind, double-dummy, placebo-controlled, parallel-group trial comparing lumiracoxib 100mg o.d. with naproxen 500 mg b.i.d. plus omeprazole 20mg o.d. and placebo in healthy volunteers to confirm the safety and tolerability of lumiracoxib in the small bowel
The primary objective of this study is to demonstrate, by video capsule endoscopy (VCE), that the percentage of subjects with one or more small bowel mucosal breaks (with or without hemorrhage) is si...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
Safety & Efficacy of BCT197A2201 in COPD patients presenting with an exacerbation
• To assess the efficacy of a single and repeated dose of BCT197 in COPD patients presenting with an exacerbation measured by the improvement in FEV1 over the first 5 days of treatment relative to pla...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
The study will evaluate the effects of BHQ880 in patients with previously untreated multiple myeloma and renal insufficiency who are not considered candidates for bisphosphonate therapy
Assess the effect of BHQ880 compared with placebo on time to first SRE in patients with untreated multiple myeloma and renal insufficiency in combination with bortezomib and dexamethasone
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A randomized, double-blind, placebo controlled, withdrawal study of flare prevention of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations
Part II: to demonstrate that the time to flare in Part II is higher with canakinumab than with placebo. Part I: to assess if canakinumab allows tapering of steroids as per protocol in at least 25% of ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A multi-centre, randomized, double-blind, placebo-controlled, two-period, crossover proof-of-concept study in patients with Fragile X Syndrome to assess the efficacy, safety and tolerability of multiple oral doses of AFQ056
- To assess the efficacy of multiple oral doses of AFQ056 in reducing the global score of the Aberrant Behavior Checklist – Community Edition (ABC-C) in FXS patients. - To assess the safety and tolera...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
Glivec (imatinib mesylate) in combination with hydroxyurea or hydroxyurea alone as an oral therapy in temozolomide resistant progressive glioblastoma patients
The main objective of the study is to show that the combination of imatinib mesylate (GLIVEC) and hydroxyurea is superior to hydroxyurea alone in prolonging progression free survival (PFS) of patients...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 12 years
and 99 years
Novartis Pharma
Update Il y a 5 ans
Étude CLTT462X2101 : Etude de phase 1 évaluant la sécurité et la tolérance du LTT462 chez des patients ayant des tumeurs solides à un stade avancé avec altérations de la voie MAPK. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Une tumeur solide est une grosseur plus ou moins volumineuse due à une multiplication excessive de cellules, cancéreuses ou non. Les tumeurs solides cancéreuses, comme les carcinomes ou les sarcomes, ...
Country
France
organs
Ovaire
,
Poumon, type à petites cellules
,
Mélanomes cutanés
,
Tumeurs solides
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Previous
23
24
25
26
27
28
29
30
31
32
Next